Who this affects

• Living people considering donating tissue (adults and children) and their families — the Act prescribes how consent must be given, certified, and revoked (ss 8–14, 24–25).
• Doctors, designated officers, hospital staff, and authorised non-doctor tissue retrieval personnel — the Act both authorises and constrains who may remove tissue and under what paperwork and checks (s 5; ss 10, 30, 31(3)).
• Next of kin and senior available next of kin — they have decision-making roles when donors have not recorded wishes, and objections by any higher-order next of kin can block authorisation (ss 27(2), 28(2); dictionary definition of senior available next of kin).
• Schools of anatomy and the Minister — the Minister authorises schools of anatomy and regulations set operating standards (ss 42–43).
• Organisations and individuals who might seek to commercialise human tissue — the Act bars contracts for valuable consideration involving tissue (s 44).
• Coroners and ACAT — the coroner can require consent to be obtained before tissue is removed or can waive that requirement (ss 29, 34, 40); ACAT orders consenting to removal of non-regenerative tissue are recognised (s 16A).

Why it matters (purpose claims and practical test)

Officially, the Act creates legal certainty for transplant and anatomical practices by specifying who may consent, how consent is certified, and when tissue may be removed or bodies retained. These are the stated operational aims (see long title and Parts 2–5).

Testing that purpose against costs, incentives and trade-offs visible in the text:

• Who pays and who benefits: the Act makes donation effectively voluntary and non‑commercial (s 44). Beneficiaries of donated tissue (individual recipients) receive the medical benefit; donors bear the privacy risk and any medical risk of removal (procedural requirements and doctor certification—ss 10, 13(2), 14(3)). The Act allows reimbursement of necessary removal expenses but bars sale for profit (s 44(2)–(3)).

• Decision power and discretion: designated officers have broad discretion to authorise removal or post-mortem after making "reasonable" inquiries (ss 27(1)–(2), 32(1)–(2), 37(1)). That centralises operational discretion in hospital-appointed officers (s 5) and creates implementation dependence on how those inquiries are carried out.

• Compliance and administrative burden: consent and certificate formalities (ss 8–10, 13(2), 14(3), 30(1)) create paperwork and require medical staff time; specialist certification is required where life support was maintaining respiration/circulation (s 30(1)) and a committee process exists for some child non-regenerative tissue cases (s 14(4)–(7)), which adds procedural layers.

• Enforcement and legal risk: criminal penalties apply for unauthorised acts (s 48) and doctors may be shielded from certain civil liability when acting under a sufficient consent or authority but remain liable for negligence (s 47). Those features incentivise strict compliance with the Act’s certification and notification steps.

• Effects on private enterprise and markets: the explicit prohibition on selling tissue (s 44(1)) constrains market transactions and contract freedom concerning human tissue. The Act permits sale of processed, non-blood tissue used for therapeutic/scientific purposes (s 44(2)), which narrows the prohibition and leaves space for certain commercial activities in processed materials under a doctor’s directions. Regulation-making power (s 51) enables further rule-setting that may affect compliance costs for educational institutions and medical providers (ss 42–43).

• Privacy and speech constraints: section 49 restricts disclosure of identifying information about donors and recipients, with exceptions for legal orders, hospital administration, medical research, and informed consent by relevant persons (s 49(4)). This limits public disclosure and sets rules for internal and research use.

• Interaction with other legal processes: coroner consent can block or permit removals and post-mortems in cases where an inquest may be required (ss 29, 34, 40); ACAT guardianship orders can authorise certain removals (s 16A). Those cross‑links add procedural complexity and can delay or prevent removals depending on parallel legal requirements.

Concrete implementation risks and trade-offs in the Act text

• Reliance on individual designated officers’ inquiries and judgments (s 5; ss 27, 32, 37) creates variation in practice across hospitals and potential delays or inconsistent outcomes.
• The Act treats objections by higher-order or any senior available next of kin as decisive (ss 27(2)(c), 28(2)), which can block consent even if one next of kin supports removal — the mechanism is explicit in the next-of-kin rules (dictionary and ss 27–28).
• The combined requirements for written consents, doctor certification, specific waiting periods for non-regenerative tissue, committee referral for some child cases, and specialist certification (ss 9, 10, 13–14, 30) increase procedural safeguards but also increase administrative cost and time-to-action.
• The prohibition on trading (s 44) reduces commercial incentives for tissue supply but the carve-out for processed tissue (s 44(2)) leaves a regulated path for commercial activity that depends on compliance with doctor directions and processing conditions.

Key sections to refer back to

• Consent and certification: ss 8–10, 13–14, 16–18, 24–25
• Post-mortem and donation after death: ss 27–31, 32–35
• Coroner interaction: ss 29, 34, 40
• Definition of death: s 45
• Prohibition on trading: s 44
• Confidentiality: s 49
• Designated officers and schools of anatomy: s 5, ss 42–43
• Offences and penalties: s 48
• Regulation power: s 51

This summary is based solely on the text of the Transplantation and Anatomy Act 1978 as supplied and cites the relevant provisions for readers who want to check the statutory mechanics themselves.